Estimates of antenatal and postpartum depression vary from 7% to upwards of 30% depending on criteria for depression, the type of assessment used, and the timing of the assessment. Thus, approximately 320,000 to over 1 million women each year experience symptoms of perinatal depression. Estimates of antenatal depression are harder to obtain because of the lack of appropriate diagnostic criteria. Despite this, no screener currently exists that has been developed and tested with both antenatal and postpartum women that uses concise, simple language, and a consistent response option set. The overall aim of this project is to develop a brief screener to assess depressive symptoms among antenatal and postpartum women. The proposed screener will be easier for patients to understand, will take less time, and will be more psychometrically sound than current screeners. In Phase I we will develop approximately 30 items that are specific to depression in antenatal and postpartum women. We will test these items using cognitive interviewing among a sample of 10 antenatal and 10 postpartum women in addition to 32 general depression items we have previously developed. Experts will review the results of the cognitive interviewing to develop the item pool that will be tested in Phase II. The Phase II item pool will consist of at least 20 general depression items, 10 items specific to antenatal women, and 10 items specific to postpartum women. In Phase II, 500 antenatal and 500 postpartum women (70% from private sector sites and 30% from public sector sites) will complete the EPDS (as a screener into the study), BDI-II, the PROMIS depression items, our items, and the depression module of the SCID. IRT analyses will be conducted on these data to develop a 7-9 item screener. We anticipate that approximately 5-7 of these items will be applicable to both antenatal and postpartum women and approximately 2-3 of these items will be sample specific. The developed screener will then be given to 400 women who will take the survey twice, approximately 4-7 days apart. Conclusions regarding test-retest reliability and patient satisfaction with taking the screener using different modes of technologies will be made from this study.

Public Health Relevance

Depression among pregnant and postpartum women has been associated with adverse health outcomes and psychopathology, both for these women and for their children and families. The proposed project aims to develop a brief, efficient screener for antenatal or postpartum depression, so that women who are depressed can be identified quickly during regular healthcare visits and can begin to receive appropriate services promptly. The proposed screener would improve upon existing measures not only through use of simpler, more concise language, but also through its development process, which entails collecting responses from pregnant and postpartum women directly.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
2P30CA023074-31
Application #
7944539
Study Section
Subcommittee G - Education (NCI)
Project Start
2009-08-19
Project End
2014-06-30
Budget Start
2009-08-19
Budget End
2010-06-30
Support Year
31
Fiscal Year
2009
Total Cost
$157,347
Indirect Cost
Name
University of Arizona
Department
Type
DUNS #
806345617
City
Tucson
State
AZ
Country
United States
Zip Code
85721
Hsu, Chiu-Hsieh; Yu, Mandi (2018) Cox regression analysis with missing covariates via nonparametric multiple imputation. Stat Methods Med Res :962280218772592
Agasid, Mark T; Wang, Xuemin; Huang, Yiding et al. (2018) Expression, purification, and electrophysiological characterization of a recombinant, fluorescent Kir6.2 in mammalian cells. Protein Expr Purif 146:61-68
Wales, Jessica A; Chen, Cheng-Yu; Breci, Linda et al. (2018) Discovery of stimulator binding to a conserved pocket in the heme domain of soluble guanylyl cyclase. J Biol Chem 293:1850-1864
Bell, Melanie L (2018) New guidance to improve sample size calculations for trials: eliciting the target difference. Trials 19:605
Lindeman, Leila R; Randtke, Edward A; High, Rachel A et al. (2018) A comparison of exogenous and endogenous CEST MRI methods for evaluating in vivo pH. Magn Reson Med 79:2766-2772
Remeniuk, Bethany; King, Tamara; Sukhtankar, Devki et al. (2018) Disease modifying actions of interleukin-6 blockade in a rat model of bone cancer pain. Pain 159:684-698
Goldenberg, Joshua M; Pagel, Mark D; Cárdenas-Rodríguez, Julio (2018) Characterization of D-maltose as a T2 -exchange contrast agent for dynamic contrast-enhanced MRI. Magn Reson Med 80:1158-1164
Blohm-Mangone, Karen; Burkett, Nichole B; Tahsin, Shekha et al. (2018) Pharmacological TLR4 Antagonism Using Topical Resatorvid Blocks Solar UV-Induced Skin Tumorigenesis in SKH-1 Mice. Cancer Prev Res (Phila) 11:265-278
Tao, Shasha; Rojo de la Vega, Montserrat; Chapman, Eli et al. (2018) The effects of NRF2 modulation on the initiation and progression of chemically and genetically induced lung cancer. Mol Carcinog 57:182-192
Russ, Atlantis; Hua, Anh B; Montfort, William R et al. (2018) Blocking ""don't eat me"" signal of CD47-SIRP? in hematological malignancies, an in-depth review. Blood Rev 32:480-489

Showing the most recent 10 out of 1336 publications